


CORPORATE FACT SHEET




Corporate Profile:

IntriCon Corporation (NASDAQ: IIN), a medical device company based in Arden Hills, MN, is committed to enhancing the mobility and effectiveness of body-worn devices that connect people to people and to devices around them. IntriCon serves the body-worn device market by designing, developing, engineering, distributing, and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for medical bio-telemetry devices, value hearing health, professional audio communication devices. Over the past several years, IntriCon has increased investments in the continued development of four critical core technologies: Ultra-Low-Power Digital Signal Processing, Ultra-Low-Power Wireless, Microminiaturization, and Miniature Transducers. These four core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable more advanced devices. IntriCon is focused on three key markets: medical, value based hearing healthcare, and professional audio communications. Utilizing this expertise IntriCon is moving to: improve margins by actively increasing the percentage of proprietary content; increase core business revenue and margins by maximizing product research and development; strengthen its leadership position in the body-worn device market by pursuing merger and acquisition opportunities. More information about the company and its products can be found at www.intricon.com.

Revenue & EPS (continuing operation) Quarterly Trends



TTM Revenue by Market from continuing operations



Stock Performance:

IIN (Common Stock)	
Exchange	NASDAQ GM (US Dollar)
Price	\$12.10
Volume Change	245%
Volume	27,600
52 Week Range	\$5.39-\$12.95
Market Cap	\$82,917
EPS from Continuing Rolling Operations	(\$0.11)
PE Ratio	110
Shares Outstanding	6,852,650

Data as of 9/30/2017

For more up-to-date stock performance information, visit the Investor Relations section of www.IntriCon.com.



INVESTOR CONTACT: SCOTT LONGVAL

Chief Financial Officer, Secretary & Treasurer

Phone 651-604-9526

slongval@IntriCon.com



Recent Events:

June 22, 2017

The Company announced that it has completed phase one, as anticipated, of the introduction of its advanced digital hearing devices into Hearing Help Express' (HHE) product line. IntriCon introduced its first digital hearing device, the EarMate 4220, into the HHE portfolio in March 2017, and just recently completed phase one of the digital offering by adding the Apollo 6200, the Apollo 6310 and the Ranger 7610 digital hearing aids.

“Digital hearing aids provide superior clarity and a better listening experience over their analog counterparts,” said Mark S. Gorder, president and chief executive officer of IntriCon. “Through HHE we’re now able to offer a lower-priced alternative for consumers to purchase technically advanced digital devices directly—circumventing layers of costs associated with the conventional hearing aid channel.”

January 19, 2017

The Company announced that it has exercised its option to acquire the remaining 80-percent stake in DeKalb, Ill.-based Hearing Help Express (HHE), a direct-to-consumer mail order hearing aid provider. Terms of the transaction include \$650,000 in cash, guaranty of HHE’s \$2 million note and an earn-out. The deal is expected to close in the first half of 2017, subject to customary closing conditions. “Completing this acquisition will give IntriCon direct access to consumers and the emerging value-based hearing healthcare market,” said Mark Gorder, president and chief executive officer of IntriCon. “HHE offers a lower-priced alternative for consumers to purchase devices directly—circumventing layers of costs associated with the conventional hearing aid channel. We look forward to building on the HHE platform by leveraging our own technically advanced devices and making targeted investments in management, marketing and advertising—and ultimately incorporating an online component.”

Financial Update:

November 6, 2017

For the 2017 third quarter, the company reported net sales of \$24.0 million, up 54.4 percent from \$15.6 million in the prior-year period. The increase was primarily due to year-over-year revenue gains from IntriCon’s largest medical customer, as well as continued traction in value hearing health. IntriCon posted net income attributable to shareholders of \$1.1 million, or \$0.15 per diluted share, versus a net loss attributable to shareholders of (\$1.3) million, or (\$0.19) per share, for the 2016 third quarter. Said Mark S. Gorder, President and CEO of IntriCon, “The future is bright for IntriCon. Our medical business is thriving, and our longer-term prospects are encouraging. Additionally, we continue to gain momentum in value hearing health, meeting critical milestones, driving sales and positioning the business for success.”

Corporate Governance:

Mark S. Gorder	President, CEO & Founder
J. Scott Longval	CFO, Secretary & Treasurer
Mike Geraci	VP, Sales & Marketing
Dennis Gonsior	VP, Global Operations
Greg Gruenhagen	VP, Quality & Regulatory Affairs

Corporate Headquarters:

IntriCon Corporation	Tel: 651.636.9770
1260 Red Fox Road	Fax: 651.636.9503
Arden Hills, MN 55112	www.IntriCon.com